Search the Community

A potentially useful resource: Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method The article includes a huge table of equivalent doses and studies. Here's the dose data extracted: Amisulpride 100 400 800 1200 Aripiprazole 2 5 10 15 20 30 Asenapine 0.4 0.8 1.6 3.2 4.8 10 20 Clozapinec 100 300 600 Haloperidol 4 4.5 6 8 10 12 15 15±5 16 20 Iloperidone 4 4–8 8 10–16 12 12–16 20–24 24 Lurasidone 20 40 80 120 160 Olanzapine 1 5±2.5 10 10±2.5 15 15±2.55 Paliperidone 1.5 3 6 9 12 15 Quetiapine 75 150 <250 250 300 400 450 600 750 800 Risperidone 2 4 6 8 10 12 16 Sertindole 8 12 16 20 24 Ziprasidone 10 40 80 120 160 200 Zotepine 75 150 300

My husband suffered a psychotic episode in his thirties with no previous history of anything like this. It was terrifying for me, seeing it happen, and watching him completely lose his mind entirely. Eventually, he was hospitalised because I just had no idea what else to do. I'd spent days arguing with him, trying to make him see sense. I didn't realise then that you can't just talk a delusional person into sanity. But what I didn't realise either was what would happen after he was put on drugs. He was made to take them in hospital and initially put on a 6mg dose of risperidone. I was supportive of that at first, not knowing what else to do and trusting the doctors. But since then he has seemed emotionless and empty. When he has felt emotion, it has been horrible things, like wishing he would die and awful dark feelings of sadness. He has no motivation or drive for anything anymore, and says he has lost all pleasure in everything in life. Eventually, five months later, after reading extensively online, we realised that it isn't just depression that is causing this - it's the risperidone. It causes brain damage. Permanent brain damage to the frontal lobe, which deals with feelings of pleasure, motivation and emotion. Neither of us knew this. None of this was explained to us. Since then, he has been tapering off the drug, but still feels 'empty'. I have read on here by other posters, who seem to post with authority, that this damage isn't permanent and that the central nervous system needs to be given time to recover. This, people have said, takes months or years. My question, however, is this: where are all the people who have recovered from risperidone? I can't find any success stories, especially not for people who were put on dosages as high as my husband was. Do people actually recover from this barbaric drug? If so, where are they? I can't find anybody, not even on here. I can't even find anybody posting on here who has been on the drug for years and hasn't recovered. What happens to all the people who have taken this drug once they come off it? Are there any patients out there who can tell me what it is like years after stopping the drug? Or any wives, husbands, fathers, mothers...anybody? I just can't believe that such a drug can not only be legal but be forced on people, if it permanently damages people in such a way.

Does anybody have Tips or something that actually worked for treating insomnia caused by antipsychotic withdrawals? The are some people like myself who had to do a pretty rapid taper because of dangerous side effects caused by years of use and a very high dose of Zyprexa. There are also some people holding back from getting off antipsychotic drugs due to the insomnia alone. I had moderate insomnia before I took Zyprexa. All of the antipsychotic drugs I've taken were for their approved use and NOT for insomnia. For myself nothing worked for the intense insomnia caused by the Zyprexa withdrawal. I tried Valium and Ambien and neither did anything. Hard exercise helped with the anxiety, depression ... but not for the insomnia. Only after I started to feel better and most of the other side effects were generally gone did anything help with the intense insomnia. I think it was at this point in my withdrawal that my brain starting to function as it did before I started taking the Zyprexa. At this point I tried Trazodone which did very little. I tried CBD oil and since I started the CBD oil, I've been sleeping well (ave 6 hours a night which is great for me). Please note, I had underlying insomnia and anxiety before Zyprexa. After the withdrawal symptoms from the antipsychotic pretty much went away, I started to feel exactly the same way I did before I started taking Zyprexa in that the underlying insomnia and anxiety that are caused by my Bipolar 1 and Anxiety Disorder returned. Zyprexa did not cause these underlying symptoms. Stopping the Zyprexa did not make me feel completely healed and normal (whatever that is). Stopping the Zyprexa got me out of the horrible brain fog and drugged feeling I had while taking Zyprexa. I do feel like I can think much clearer and have emotions again. Antisychotics took all that away. For me, I couldn't find that magic bullet to get rid of the insomnia caused by the antipsychotic withdrawal. I think the insomnia during withdrawal is completely different than the insomnia I experienced before by the use of the antipsychotic. I don't think there's anything that can be done to treat the insomnia caused by the antipsychotic withdrawal. The antipsychotic drugs are so powerful that the withdrawals can't be treated. I think the withdrawals can be controlled by a very low dose reduction and very slow taper as recommended by SA. For some people a 5% or 10% drop might be too much. If it is, try less. Everybody is different. I think your body will tell you how much of a dose reduction to make. You may be able to tolerate 10% or even 25% or as low as 1% or 2%. Nobody can tell you for sure. Pick a number and try. I wish I had that option. If anybody knows anything that helps the insomnia during the antipsychotic withdrawals, please share. For me, adding bandaid drugs didn't work. Even share your thoughts about timelines you experienced when your symptoms started to diminish. All of this would have helped me.

hello there. i registered here to search for help for symptoms that are bothering me and that came after 15mg of olanzapine for 7-8 months. generally, i've been taking olanzapine for like a year or something, i started with a 5mg dose at 2015, after some time they upped it to 10mg, and then i've had a full-blown psychotic episode and i began taking 15mg. i was hospitalized and there they gave me high doses of 5 different medications. when i came back home, things just weren't the same. okay, that didn't bother me, i was still thinking that it's only a phase. then, month after month, i realized that that "phase" is actually... something deeper, different. so i searched about it on the internet; and saw that "antipsychotics destroy brain". i stopped taking olanzapine cold turkey, which was DEFINITELY a very bad idea. at first, i was very depressed, i don't know if it lasted long enough to be called a major depressive episode, but it was severe. i was full of guilt... but, the worst of it all - i couldn't feel a damn thing. i couldn't enjoy a damn thing. i was on a winter holiday and i'm a skier, but i didn't feel anything while i was skiing. yes, i could leave a bed, but i was doing it only because i felt like the world around me would judge me and criticize me if i didn't. people are supposed to feel happy, free when they're skiing, even scared. i didn't feel anything. i realized that i stopped caring about everything, so, you could tell me a good thing - i would feel nothing (sometimes it was even hard to fake a smile, because it was even hard to move my face). you could tell me a bad thing - i would feel nothing. i had a fear of being criticized, but now, that faded too. but that's okay, to be honest, it's much easier to live without the guilt and at the same time energy to do anything about the guilt you're feeling. and i wanted to feel things. i wanted, and not only wanted, but i still want to feel things. deeply. so i started faking reactions to things... i was like - okay, imagine you're a normal person who didn't go through this kind of situation. how would a normal, rational person react ? and then i reacted that way. i still do that tho, it became some kind of a habit. my concentration is very bad. my will is very bad. i have anhedonia and apathy. my cognitive abilities are awful. but i just can't seem to care. and you know, sometimes you feel bad for not caring about things. i don't even feel bad about not caring, i just don't feel a damn thing. i had a period where i was doing better and was motivated to recover. i still want to recover, but i feel like nothing makes sense and i don't know how to get out of this nonsense. if any of you found sense, can you please tell me how ? i know it's an extremely hard and long process, but i somehow believe that it's possible. WHY ? i went to the neurologist and spent a lot of money on some neurological tests, for example magnetic resonance imaging of the brain. guess what ? IT'S NOT THE BRAIN. IT'S PSYCHE. mind. mental. !!!!!!!!!!!! at least for me. tests can't and don't lie. i believe in those tests, even tho i have all the symptoms of brain damage, i surely don't have a brain damage because i have an evidence. the tests have shown that my brain is perfectly healthy, despite my mental disorder. i don't know about you, but i can recommend checking yourself just to be sure, it can ease the pain, even if you do have a brain damage or if you don't. if you don't have enough money, there are local hospitals where you can check yourself. so that's why i accepted medications and i'm currently using 10mg of escitalopram and i started few days ago aripiprazole 5mg. i'm willing to try things. i just feel so brain-foggy and that's stopping me from doing anything. and now, i'll go and search the forum for some advices from you guys, i will write here again. thanks if you read this. ...and yeah, sorry for a really bad post, i'm not so well right now. i'm glad that i became the part of this community, the feeling that i'm not alone makes me feel better. and it's hell.

Hi, I have been on olanzapine since December 2014 (2.5 years). I started at 10 mgs, then went to 5 mgs after 2 months. I then dropped to 2.5 mgs. Last August, I started 1.25 mgs day and stayed there until July 2017. I am now doing .625 mg/day since July 6. I am cutting this from a 5 mg pill. I am on no other medications. I stopped seeing my psychiatrist last Aug. I lost my insurance then. I have been doing really well and feel like I will be ok coming off. Even when I was seeing the doctor, I told him I could not stay on this forever as I've gained 30 lbs and I am afraid of diabetis, the dulled effect to my personality and other side-effects. I lapsed into a depression that lasted a few months when dropping under 2.5 mg. I felt with absolute certainty that it was caused from tapering down the medication and not a return of any illness. The depression lifted suddenly back in the spring and I've felt more like my old self than I have in years. The only side-effect I seem to have right now from the taper is difficulty sleeping some nights. It's not every night...probably 3 nights a week that I wake up several times in the night. I don't know where to put my question but I'd like to know if anyone has successfully come off olanzapine (Zyprexa) and when they did the final jump. I am taking such a small crumb of pill that I don't think I can cut it anymore. I am thinking that my next step will be to do .625 every other night. I feel happier today than I ever did while on olanzapine. It depressed the heck out of me and blunted my emotions greatly. I look at this tiny crumb I take every night and wonder if it is doing anything at all. Can anyone direct me where to go to post my questions? Thank you!

I was put on risperidone 3,0.5mg in the morning and 2mg at bedtime for 3 months, but not only that i was misdiagnosed and its been 4 months off it now and I also cant feel anything, happiness, sadness, creativity, joy, zest for life is gone. my scense of wonder is gone and I have alot of cognitive problums now to like not being able to think right, im slow. I used to love music but now it dosent stimulate me. i cant feel ciggeretts or injoy video games like I used to. im loseing all my friends because there like WTF man and im only 24. I doubt an antidepressant is going to do anything. I was on Celexa but stopped it after 3 weeks because what im feeling is from risperidone not depression. now I also have an inability to communicate, I dream EVERY NIGHT. I cant stay focused anymore I used to build projects from wood but nope, cant do that anymore ither. I used to laugh love injoy parties some of my friends even said i was the life of the party. well, not anymore thats for sure. I dont evin remember what I did a half hour ago. this drug ruined my life so far: my birthday, christmas, family events. my family is wondering what the hell happend to me. I NEED TO RECOVER. ive been chemically lobotomized. at least I can still type to find support on the internet. if i knew they were antipsychotics i would of never takein them. the doc never explained anything to me!, the only things I do feel really is worried i wont come out of this, and being hungry, all i think about now is why did i take these meds and will i ever recover. someone please respond with something positive did anyone recover from this and how long did it take. I ended up in the psyc ward because I smoked weed that was soaked in bleach and I tripped out. never knew the weed was tampered with at the time and then I was misdiagnosed with psycosis. I dont think the bleach weed did any real damage because when I woke up in the hospital I was ok but I was givein risperidone and sent home I should of never took the risperidone. but I did for three months, anyway. long story short I need support in knowing if ill get my emotions and personality back.

Hello, I have been reading this site for over a year. I've taken antipsychotics for about 27 years & decided to taper off. My GP is supportive of a slow taper lasting years. I'm currently taking 5mg trifluoperazine - original brand name Stelazine- and 12.5 mg procyclidine. I filled in my history in the signature. data17

This paper is one of the most thorough I have come across in relation to its topic: Supersensitivity Psychosis, the reason antipsychotics are in fact pro-psychotics. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy Chouinard G.a,b,g · Samaha A.-N.c, d · Chouinard V.-A.e, f · Peretti C.-S.g · Kanahara N.h · Takase M.i· Iyo M.h, i It's long and thorough - over an hour at 200wds/pm The lead author, Guy Chouinard, is notable for his role in identifying this phenomenon in 1978. This blog post has a little more background on Chouinard. Although the content may be a little on the technical side, which is say more of interest to laboratory researchers, the paper proposes diagnostic guidelines. Whether or not these will make it into future manuals such as the DSM and ICD remains to be seen, however it would be interesting to see how this would sit alongside modern descriptions of disorders, many of which have absorbed the side effects of medications into their lists of symptoms, thereby masking them, and leading to ever-increasing doses. I think the descriptions of what is drug-induced versus what is a latent problem may potentially be useful. The fact that it recognises a distinction and attempts to define it at all is fairly noteworthy. I've included that section, preceded by the abstract, and links to the original content. This comes to around 6000 words - about 30 minutes reading. Abstract The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation. In the era of first-generation antipsychotics, 4 clinical features characterized drug-induced SP: rapid relapse after drug discontinuation/dose reduction/switch of antipsychotics, tolerance to previously observed therapeutic effects, co-occurring TD, and psychotic exacerbation by life stressors. We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable risperidone, olanzapine, quetiapine, and aripiprazole). These studies show that the prevalence rates of SP remain high in schizophrenia (30%) and higher (70%) in treatment-resistant schizophrenia. We then present neurobehavioral findings on antipsychotic-induced supersensitivity to dopamine from animal studies. Next, we propose criteria for SP, which describe psychotic symptoms and co-occurring movement disorders more precisely. Detection of mild/borderline drug-induced movement disorders permits early recognition of overblockade of D2 receptors, responsible for SP and TD. Finally, we describe 3 antipsychotic withdrawal syndromes, similar to those seen with other CNS drugs, and we propose approaches to treat, potentially prevent, or temporarily manage SP. Introduction Pharmacological Mechanisms by Which Antipsychotics Potentially Increase D2 Receptor Density and/or Function Clinical Characteristics and Consequences of SP in the Era of SGAs Evolving Conceptual Framework of Antipsychotic-Induced Dopamine SP in Line with Other CNS Drug Withdrawal Syndromes Pharmacological Link between a Compensatory Increase in D2/D2High Receptor Density and SP Guidelines for SP and TD Prevention Choice of the Antipsychotic Guidelines for SP Treatment Guidelines for the Management of Antipsychotic Withdrawal Evolving Conceptual Framework of Antipsychotic-Induced Dopamine SP in Line with Other CNS Drug Withdrawal Syndromes Classification of Antipsychotic Withdrawal Syndromes Based on ongoing research into SP characteristics, along with evidence for withdrawal symptoms found with other CNS drug classes, we present a conceptual framework [1,41] for identifying SP and other antipsychotic withdrawal syndromes (Tables 1, 2). Chouinard and colleagues [1,31,89,90] reported 3 types of withdrawal syndromes associated with CNS drugs, including opiates, barbiturates, and alcohol: (1) new or classical withdrawal symptoms; (2) rebound; and (3) postwithdrawal disorders (Table 1). These 3 types of withdrawal syndromes need to be differentiated from relapse and recurrence of the original illness. Relapse is defined as the gradual return to symptoms seen before treatment and entails a return of the ongoing episode, while recurrence is defined as a new episode of the illness (Table 1). Table 1 Type of antipsychotic withdrawal compared to relapse and recurrence [41] Table 2 Diagnostic criteria for new symptoms induced by antipsychotic treatment New and rebound symptoms occur up to 6 weeks after drug discontinuation/dose reduction/switch, depending on the drug terminal plasma half-life (t1/2). New and rebound symptoms of CNS drugs have been reported to be more frequent and severe with short t1/2 and high-potency drugs [1,31,89,90]. New and rebound withdrawal symptoms are usually of short duration, persisting for a few hours to 2 weeks with complete recovery. However, if symptoms persist for more than 6 weeks, they become part of postwithdrawal disorders [41]. Fava et al. [91] proposed to replace the term discontinuation syndrome often used for selective serotonin reuptake inhibitors (SSRIs)/selective noradrenaline reuptake inhibitors (SNRIs) [92] and antipsychotic medications [93] by “withdrawal.” CNS withdrawal occurs when the pharmacological effects of a drug diminish during medication discontinuation/dose reduction/switch, or in-between doses, which indicates an underlying pharmacological mechanism. The term discontinuation refers to the medical act of drug discontinuation or patient self-discontinuation. Furthermore, the term discontinuation is misleading since withdrawal symptoms may also occur with dose reduction or in-between doses for rapid-onset short-acting drugs. Examples include alprazolam and lorazepam, which can induce clock watching in-between doses, and clozapine which can induce late afternoon psychosis when given as a single dose at bedtime [41]. We will give criteria for each of the 3 types of withdrawal associated with antipsychotics [1,41,94]. New Symptoms New symptoms are the classic symptoms of withdrawal. They are not part of the patient's illness. New symptoms can be minor (anxiety, insomnia, and tremor) or major (seizures, psychosis, and death) [95]. Some are common to all CNS drugs, including narcotics, barbiturates, and alcohol, but each class of CNS drugs has its own specific new symptoms [1,41,90]. New symptoms common to CNS drugs include: nausea, headache, tremor, sleep disturbances, decreased concentration, anxiety, irritability, agitation, aggression, depression, or dysphoria [41], as listed in Tables 3 and 4. On the other hand, new drug-specific symptoms are linked to receptor binding affinities, and result from receptor supersensitivity which leads to increased neurotransmission due to removal of receptor blockade by antipsychotic treatment when medication is discontinued or switched, or dose is reduced [1,41,90]. New and rebound symptoms occurring during withdrawal and switch from and to SGAs (aripiprazole, asenapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, and amisulpride) were reviewed recently by Cerovecki et al. [94]. In Tables 1 and 2, we integrate some of their findings on treatment-emergent symptoms related to removal of blockade or stimulation of dopamine and other receptors (serotonin, muscarinic, adrenergic, and histaminic receptors) by SGAs [94], and divide new antipsychotic-specific symptoms into: (1) serotonin withdrawal syndrome (equivalent to serotonin syndrome): flu-like symptoms, diarrhea, disorientation, coma, hyperreflexia, and stimulus-inducible clonus; (2) muscarinic withdrawal syndrome (also called cholinergic rebound syndrome): nausea, vomiting, abdominal cramps, hypothermia, increased salivation, tremor, parkinsonism, restlessness, and insomnia; (3) adrenergic withdrawal syndrome: increased blood pressure, headache, anxiety, agitation, increased heart rate, myocardial infarction, angina pectoris, palpitation, chest pain, presyncope, tremulousness, sweating, increased heart rate, myocardial infarction, hyperthermia, and fear; and (4) histaminic withdrawal syndrome: insomnia, agitation, tremulousness, increased seizure susceptibility, and amnesia (Table 2). Some new symptoms (Table 2) have been reported to occur more than 6 weeks after discontinuation: myocardial infarction and death after discontinuation of β-blockers [96]; hyperreflexia and inducible clonus after abrupt discontinuation of clozapine [97]; inducible seizure after discontinuation of chronic H1antihistamine treatment in rodents [98], and persistent insomnia following drug discontinuation/dose reduction of central muscarinic anticholinergics [1,90], and alcohol [95]. Table 3 Diagnostic criteria for rebound psychosis induced by antipsychotic treatment Table 4 Diagnostic criteria for persistent postwithdrawal supersensitivity psychosis induced by antipsychotic treatment Rebound Rebound Syndromes Associated with CNS Drugs The second type of CNS drug withdrawal consists of rebound symptoms (Tables 1, 2) [41]. It refers to a sudden return of patient symptoms above pretreatment levels and is usually short lasting. Rebound symptoms should be distinguished from pharmacological rebound, which produces both new and rebound symptoms. Pharmacological rebound is caused by a sudden increase or decrease in receptor-mediated effects due to removal of receptor blockade following drug discontinuation/dose reduction. This includes adrenergic rebound [99], cholinergic rebound [100,101], serotonin rebound [97], and histamine rebound [98]. We make a distinction between new and rebound symptoms, though they may have the same pharmacological mechanism [1,41,94]. The difference between new and rebound symptoms is whether present before treatment and known to the patient (rebound) or not present before treatment (new) and known to the patient. Cholinergic rebound produces both new symptoms: nausea, vomiting, salivation, abdominal cramp, diarrhea, hypothermia, tremor, insomnia, depression, and rebound symptoms listed in Tables 1 and 2; adrenergic rebound produces increase or “overshoot” in blood pressure and in heart rate above pretreatment and is also associated with new symptoms such as insomnia and anxiety [99,102]. Rebound anxiety and insomnia, seen with short-acting benzodiazepines [1], are also associated with new symptoms [103]. Withdrawal insomnia [104] and rebound insomnia [105] were identified as separate entities in all-night EEG recording studies. Recently, we reviewed CNS drug rebound syndromes [41]. Several CNS drug rebound syndromes have been reported to occur following drug discontinuation after short-term use: REM rebound with barbiturates and non-benzodiazepine hypnotics [106,107]; rebound myocardial angina and infarction with propranolol [108]; rebound insomnia [105], rebound anxiety [103], and rebound panic [109], with benzodiazepines with short and intermediate t1/2(triazolam, lorazepam, and alprazolam); and rebound depression [1,41]. Rebound depression has also been observed at a greater frequency with high-potency (paroxetine) and/or short-acting SSRIs and SNRIs [1,41]. In 2 double-blind placebo studies, patients with major depression had their maintenance paroxetine, sertraline, or fluoxetine treatment interrupted with placebo substitution and treatment reinstitution [110,111]. In one of the studies [110], patients taking paroxetine and sertraline had a sudden worsening of depressive symptoms upon drug discontinuation with a return to baseline depression measurements after reinstitution of the treatment. In both studies [110,111], patients taking fluoxetine did not have rebound depression, confirming that fluoxetine with a long t1/2 including norfluoxetine is less likely to cause rebound [41]. In contrast, patients treated with paroxetine had rebound depression in both studies [41,110,111]. The prevalence of high-dose use [112] is greater among patients taking benzodiazepines with short-intermediate t1/2 (e.g., triazolam, lorazepam, and alprazolam) than patients taking benzodiazepines (clonazepam, clobazam, and diazepam) with long t1/2; these differences persist even after 12-year long-term use [112]. Rebound syndromes respond rapidly to reinstitution of the offending drug, which often leads patients to false beliefs about efficacy and need for the drug [90]. The psychological belief of needing the drug for fear of having symptoms return appears the same for short-acting and short t1/2 CNS drugs, including antipsychotics (quetiapine) [1], paroxetine (SSRI) [41], lorazepam [103], alprazolam [112], cocaine [113], and heroin [114]. Rapid-onset drugs with short t1/2 will have an increased risk of rebound upon withdrawal, as illustrated by cocaine and heroin [114]. Rebound symptoms can be persistent in some patients, for example long-lasting insomnia after withdrawal from sustained alcohol abstinence [95] and rebound psychosis after long-term antipsychotic treatment [1,14]. Rebound Psychosis The proposed diagnostic criteria for rebound psychosis are given in Table 3. Rebound psychosis is defined by a rapid return above pretreatment levels of at least one positive symptom listed in the Rating Scale for Psychotic Symptoms (RSPS) [73,74]. Rebound psychosis lasts up to 6 weeks after peak onset (Table 1); if it persists longer, it becomes a postwithdrawal disorder, as for new symptoms persisting more than 6 weeks. Rebound psychosis is generally short lasting and considered as a reversible form of SP, equivalent to reversible withdrawal TD [1]. Any rebound symptom, such as an increase in blood pressure, myocardial infarction, insomnia, or psychosis, has the potential to become a persistent postwithdrawal disorder when lasting more than 6 weeks, often lasting several months and even years [1,41,95,96]. As with other CNS drugs (benzodiazepine, SSRI/SNRI, heroin, and cocaine), antipsychotics that are rapidly eliminated and/or that rapidly dissociate from the D2 receptor including clozapine (time to peak concentrations in plasma, tmax: 3-4 h; t1/2: 16 h [115]) and quetiapine [116] (tmax: 1-1.8 h; t1/2: 7 h [115]) have greater risks of rebound when medication is reduced, switched [59], or discontinued [1,33,39,40]. Patients on clozapine monotherapy taken as a single dose at bedtime report late afternoon return of symptoms [1]. For both the immediate-release formulation (IR) and the extended-release formulation (XR) of quetiapine, it is common in clinical practice to have difficulty in decreasing the drug dose, as it causes rebound anxiety and rebound insomnia (the drug possessing anxiolytic and hypnotic effects [117]), and later causes an in-between dose clock watching for return of symptoms, e.g., patient watches the clock to make sure the next dose is not missed for fear that symptoms might return, when given once a day above 150 mg [117] over a 2-month period [1,41]. The pharmacokinetics [118] and the central D2 receptor occupancy pharmacodynamics [119] of IR quetiapine given twice daily and XR quetiapine given once daily are similar [118,119]. Rebound psychosis with SGAs was first seen with clozapine [33] and then quetiapine monotherapy [39], but was later seen with all SGAs [34,35,36], with overt prevalence depending on drug t1/2 and potency. Quetiapine and clozapine have a particular D2 pharmacological profile compared to other SGAs: loose binding displaced rapidly from the D2 receptor [120], fast dissociation from the D2receptor [116], brief and weak action of clozapine on brain dopamine systems [116,121], and high transient initial D2 occupancy by quetiapine with minimal occupancy at the end of the dose interval [122]. This D2 profile of clozapine and quetiapine leads to differences in SP manifestations [1]: elevated incidence of rebound psychosis with clozapine [1,33,39,101], which is a reversible withdrawal subtype of SP [1], and severe drug tolerance with IR quetiapine given as antipsychotic monotherapy [39]. This might be explained by initially high D2 occupancy followed rapidly by low occupancy at the end of the dosing interval [122]. Postwithdrawal Disorders Postwithdrawal Disorders of CNS Drugs Postwithdrawal disorders have been described with all classes of CNS drugs [1,41]. Early recognition of postwithdrawal disorders for a given class of drugs is facilitated by the presence of high-potency drugs combined with short t1/2 [1,123,124]. Due to the short duration of action, there is a rapid decrease in occupancy of receptors produced in greater number by potent blocking drugs, thus resulting in a greater number of receptors in their unblocked state [1,108,123,124]; this was the case for β-adrenergic blocking drugs. As early as 1975, dose was highlighted as an additional factor for early recognition of postwithdrawal disorder; 160-320 mg propranolol/day would produce an adrenergic rebound unmasked rapidly by discontinuation, which led to an increase in cardiac contractibility, heart rate, myocardial ischemia, and rapid death, even after short-term use (6-12 weeks) [108]. Interestingly, in this first report of adrenergic rebound, major complications such as death were seen in patients who responded better to propranolol [108], which is also a characteristic of SP, most often seen in good antipsychotic drug responders [14,72]. Following abrupt withdrawal (even gradual withdrawal) of β-adrenergic drugs after long-term use, it was relatively easy to demonstrate an overshoot adrenergic rebound with pretreatment symptoms reappearing suddenly - increase in blood pressure, heart rate, myocardial infarction, headache, and anxiety above pretreatment levels [96,102]. The early recognition of supersensitivity rebound with β-adrenergic drugs helped to identify its underlying receptor supersensitivity mechanism through catecholamine stimulation by isoprenaline (isoproterenol), a nonselective β-adrenergic receptor agonist in patients [99,124,125], and later identify persistent postwithdrawal disorders consisting of an increased risk of myocardial infarction and mortality following their discontinuation [96]. Houston and Hodge [102], in their review of β-adrenergic blocker withdrawal syndromes, described 7 studies showing rebound and persistent withdrawal with 80 mg/day propranolol and a study showing these withdrawal syndromes after only 7 days of propranolol use. Doses below 80 mg propranolol/day appear safe to use in psychiatric clinical practice, but gradual dose reduction of low-dose propranolol is also recommended especially in patients at risks of myocardial infarction and essential hypertension. Rebound anxiety and insomnia were also first demonstrated with short-acting and potent benzodiazepines [90,103,105], and later as postwithdrawal disorders for alcohol [95] and benzodiazepines [104,126]. Other known postwithdrawal disorders are major depression and dysphoria in cocaine [113,114] and amphetamine withdrawal [114]. Within a drug class, specific drugs such as fluphenazine, perphenazine, quetiapine, clozapine, triazolam, and paroxetine permitted identification of new postwithdrawal disorders [1,33,39,41,109,127]. For SSRIs and SNRIs, several postwithdrawal disorders after long-term use have been described; interestingly, these postwithdrawal disorders consist of disorders that can be treated successfully by SSRIs and SNRIs, such as obsessive-compulsive, panic, generalized anxiety, and gambling disorders [1,41,109,127,128,129]. All these postwithdrawal disorders have been shown to occur more frequently with paroxetine [41,109,129,130]. This suggests that paroxetine should not be used anymore. For antipsychotics, two persistent postwithdrawal disorders, TD and SP, have been described [14,28,30,31,131]. When the symptoms last less than 6 weeks, they are considered as withdrawal dyskinesia and rebound, or withdrawal psychosis, respectively. When the symptoms last longer, they become postwithdrawal disorders, TD, or SP [1]. Discontinuation of short- and long-term β-blocker therapy can uncover long-lasting β-adrenergic supersensitivity [96,99]. Similarly, it has been known since the 1970s that long- and short-term dopamine receptor blockade by antipsychotics can both produce receptor supersensitivity [132]. The persistence of the dopamine supersensitivity syndrome depends on the duration of the preceding blockade [132] and on the specific antipsychotics used (fluphenazine, perphenazine, clozapine, and quetiapine) [1,41]. Similarly to β-adrenergic supersensitivity which may occur early and severely with β-blockers [108], TD can occur after short-term use (1 month) of chlorpromazine (FGA) in a patient with schizophrenia [133], and in a nonpsychiatric patient after a 4-month treatment with a gastric preparation containing trifluoperazine (FGA) and an anticholinergic drug [134] in an irreversible and extremely severe form. Supersensitivity Psychosis The proposed diagnostic criteria [14] for SP as a CNS postwithdrawal disorder [41] are presented in Table 4. The criteria take into account results from the 3 recent studies in patients treated with SGAs (n = 505) reviewed above [34,35,36], which examine the clinical characteristics of SP, 2 specifically focusing on TR schizophrenia (online suppl. Table 2). In addition, we took into account the results from the 2 studies by Fallon and Dursun [37 ]and Fallon et al. [38], which examined the link between SP and relapse in treatment-adherent schizophrenic patients without drug discontinuation who were not taking clozapine or quetiapine [37,38]. Exacerbation of psychosis by dopamine partial agonists was added as a risk factor (minor criterion) following the study by Takase et al. [36]. Vulnerability to minor life events was explicitly added to the minor criterion of exacerbation of psychosis by stress, following the results of Fallon and Dursun [37 ]and Fallon et al. [38]. Finally, the criteria define severe therapeutic drug tolerance more precisely as a nonresponse to doses equivalent to ≥600 mg chlorpromazine/day/12 mg haloperidol/day, when the patient has previously responded to lower doses. In addition, compared to 1991 criteria, major criteria define positive symptoms specifically [73,74]. Major criteria C2, C3, or C5 do not need minor criteria as was shown by the SP criteria used in the 3 recent Japanese studies of SP (n = 505), which included both patients with and without TR schizophrenia (online suppl. Table 2) [34,35,36], and in the 2 relapse studies [37,38]. Major criteria define rapid psychotic exacerbation or relapse upon drug discontinuation/dose reduction/switch of antipsychotics, and drug tolerance which refers to the lessening of drug therapeutic effects with continued treatment and the need for increasing doses to achieve the same beneficial effect. Minor criteria are risk factors for SP (Table 4); they help to identify patients at risk for SP relapse. One minor criterion is needed if only one of the major criteria present is C1, C2, or C6 (Table 4). We will now describe how SP criteria might be linked to an increase in D2/D2High receptor density. Pharmacological Link between a Compensatory Increase in D2/D2High Receptor Density and SP All antipsychotics, including the most recent SGAs [26], have the potential to produce D2upregulation. For instance, using laboratory animals, Tarazi et al. [135] reported upregulation of D2 receptors by olanzapine, risperidone, and quetiapine. Kusumi et al. [136] showed an increase in striatal D2 density following subchronic treatment with doses of chlorpromazine and perospirone (SGA) that produce therapeutic levels of striatal D2 receptor occupancy but not with low doses of chlorpromazine, risperidone, and olanzapine. While some antipsychotics may not elevate the density of D2 receptors, they can still raise the number of dopamine D2High receptors [25]. The increase in the number of D2 and/or D2High receptors enhances dopamine-mediated transmission [4] (Fig. 1). This may lead to more severe psychosis than seen in previous episodes during SP relapse or exacerbations, with new schizophrenic symptoms of greater severity such as disorganized behavior [14]. Patients with SP are more vulnerable to stress [14,69], minor life events, and daily hassles [14,37,38,69]. Stress increases dopamine levels in the brain [137]. In the presence of increased D2/D2High density, stress-induced dopamine in the extracellular space will produce greater D2-mediated signaling, leading to vulnerability to minor life events in patients with SP [14,69] even without drug discontinuation/dose reduction [37,38]. SP patients without drug discontinuation/dose reduction could be considered as having an overt form of SP [1,14]. As dopamine binds to D2receptors in competition with antipsychotic drugs, antipsychotics with less D2 receptor affinity allow more dopamine to bind to the receptors, and psychotic relapses due to SP will appear more rapidly. Another feature of SP is the gradual tolerance to the therapeutic effect of antipsychotic medications, where previously efficacious doses can no longer adequately control psychotic symptoms. Continuous D2 occupancy by antipsychotics, within or above the threshold for prolactin and movement disorders (i.e., in the 72-78% range [4,138]), increases D2 density as a compensatory reaction to reduced dopamine-mediated signaling. As D2 density increases, the therapeutic level of D2 occupancy (65%) [4,138] becomes higher [4], and previously efficacious doses are insufficient to suppress or cover psychotic symptoms. In order to improve psychotic symptoms, at least temporarily, higher doses are required [20], and therapeutic drug tolerance further develops. This has also been shown in animal models of antipsychotic-like efficacy, where continuous blockade of D2 receptors by antipsychotics, at clinically representative levels, produces tolerance to ongoing treatment, and higher doses can temporarily restore efficacy [9,10]. The optimal range of D2 occupancy in drug-naïve schizophrenia has been established [138], and theoretically determines the optimal dose range for antipsychotic drugs [4]. Therefore, patients who previously responded well to antipsychotics, but now have become poor responder or have histories of maintenance treatment with doses equivalent or higher than 600 mg chlorpromazine/day and 12 mg haloperidol/day are at increased risk for SP. Poor response to 2 antipsychotics at doses equivalent to or higher than 600 mg chlorpromazine/day is a criterion for TR schizophrenia [75,76]. Following antipsychotic discontinuation or sudden dose reduction, psychotic relapse develops more rapidly in patients with SP than in those without [69]. As the antipsychotic drug is eliminated with its specific t1/2, endogenous dopamine would now have access to a greater number of D2 and D2High receptors (Fig. 1), explaining why psychotic symptoms appear more rapidly in SP patients during drug discontinuation/dose reduction/switch of medication. However, the delay before the appearance of psychosis will also depend on the t1/2 of each drug. As optimal therapeutic D2 occupancy increases [4], increasing the antipsychotic dose would further mask TD [139] and SP [1], produce parkinsonism and negative symptoms, but also temporarily improve positive symptoms [4,34]. Some patients with severe SP who are also taking high doses of antipsychotics may exhibit all of these symptoms at the same time [1,34,140]. This mixed syndrome of drug-induced movement disorders and psychosis is temporally improved by giving the antipsychotic in divided doses [69]. Thus, SP may be masked, overt, or mixed [1], like TD [19]. The fact that SP can be overt during dose reduction, and masked by the causing drug during treatment [14,28,30], explains the therapeutic tolerance observed when antipsychotics can no longer mask psychotic symptoms at previously efficacious doses, and further increases in doses are necessary to obtain similar therapeutic effects [14,28,30]. Tolerance needs to be identified early to avoid increasing doses. Once therapeutic tolerance is identified, instead of dose increases to cover SP, strategies that we propose here should be considered, primarily the use of low doses of antiseizure drugs [1], the use of the minimal therapeutic dose of antipsychotic, and regular but intermittent dosing. Switching from one antipsychotic to another can potentially induce or uncover SP [14,37,69,94]. Switching antipsychotics will allow SP to emerge in patients either with or without a past history of SP [36]. This suggests that a medication switch can unmask SP induced by previous antipsychotic treatment, particularly in patients taking doses equivalent to ≥600 mg chlorpromazine/day/12 mg haloperidol/day. SP often occurs in the presence or history of drug-induced movement disorders, most often parkinsonism or TD [14,28,30,37]. This is expected since parkinsonism and other drug-induced movements are the best predictors for TD [1,71,81] and SP [1,37,38]. As striatal D2 occupancy by antipsychotics exceeds 65%, a clinical response is likely to appear, hyperprolactinemia when >72% and parkinsonism and movement disorders when >78% [138]. The therapeutic window of 65-72% D2 occupancy proposed by Kapur et al. [138] in their PET study of first-episode schizophrenia is relatively narrow and corresponds to doses >0.5 mg haloperidol/day [138]. Iyo et al. [4] suggested to extend the therapeutic window to >78%, i.e., when movement disorders appear, since movement disorders are easier to detect clinically and also because not all antipsychotics increase prolactin. Therefore, continuous D2 occupancy by antipsychotics above the narrow therapeutic window of 65-72% [138] or above the 72-78% threshold for prolactin/movement disorders may produce undetected parkinsonism and SP [1,4,19,28]. As already mentioned, Kapur et al. [138] found that the threshold level of striatal D2 receptor occupancy for movement disorders is >78% in first-episode schizophrenia. While catalepsy is seen in rats with doses that occupy >80% [141,142], dopamine supersensitivity can be seen at doses that occupy <80% [9,10,11,12]. Indeed, in animal models of dopamine supersensitivity, the doses we have studied occupy 73-74% of striatal D2receptors [9,10,11,12]. Table 5 Guidelines for the prevention of supersensitivity psychosis (SP) and tardive dyskinesia (TD) The second step (Table 5) is the administration of minimal therapeutic doses during maintenance treatment following the acute phase. The dose given in the acute phase is reduced gradually when initiating the maintenance treatment [148]. During the acute phase of psychosis, excessive dopamine release competes with antipsychotics for D2 receptor binding and depletes dopamine in the synaptic cleft [149], which creates a delay in reaching a new equilibrium. The third step (Table 5) is to keep D2 occupancy within the optimal therapeutic range while maintaining the minimal therapeutic dose. This must take into account the side effects and patient's tolerability, which could be predicted by 4 pharmacokinetic parameters (clearance, volume of distribution, t1/2, and bioavailability) [150]. In clinical practice, one should take into account that peak-to-trough plasma concentrations vary greatly and will depend on a number of variables. These include dosing interval and drug formulation [151], D2 receptor affinities, lipophilicity, active metabolites, patient characteristics (ethnicity and gender), concomitant medications, comorbid diseases, and general physical health [151,152]. While it is generally agreed that for oral SGAs (risperidone, olanzapine, clozapine, quetiapine, and ziprasidone) pharmacokinetic parameters are not sufficient for selection [115], selection of SGAs should be based on efficacy, side effects/tolerability, drug discontinuation-induced withdrawal symptoms and postwithdrawal disorders [1], and drug formulations [4,151]. For LA injectable antipsychotics, pharmacokinetic data in product monographs are of limited value for clinicians to choose the interval of administration [153]. In their recent review, Lee et al. [153] recommend using t1/2 for LA injectable SGAs to decide on the dosing interval in clinical practice. Continuous blockade of D2 receptors could contribute to the emergence of SP according to research conducted in animals. This work shows that when using the same achieved dose, peak level of D2 receptor occupancy, route, and duration of treatment, continuous antipsychotic treatment/D2 receptor blockade (as achieved via subcutaneous osmotic minipump) favors dopamine supersensitivity, while intermittent treatment/D2 receptor blockade (via daily subcutaneous injection) does not [9,11,154]. There are reports that intermittent antipsychotic administration via daily subcutaneous injection can produce dopamine supersensitivity [155,156,157,158]. However, the antipsychotic doses used are quite large and would produce excessively high and clinically unrepresentative levels of striatal D2 receptor blockade [159]. Continuous antipsychotic treatment could promote dopamine supersensitivity because it disrupts dopaminergic signaling unremittingly. This evokes compensatory changes including an increase in the number of striatal D2 and D2High receptors in the striatum (Fig. 1) [9,10,50]. In contrast, intermittent antipsychotic treatment allows at least some level of dopaminergic signaling to occur in between peaks in D2 receptor occupancy. This might be sufficient to prevent the brain changes that produce dopamine supersensitivity. The challenge is how to define “intermittent treatment” in clinical research and clinical practice. The clinician will often use short interdosing intervals (e.g., not taking antipsychotics on the weekends), to achieve minimal therapeutic dose [1]. In patients, there is likely a “break point” where if the antipsychotic dose/striatal D2 receptor occupancy has been low enough for long enough, the treatment might not be efficacious anymore to prevent relapses, thus being below the minimum therapeutic dosing. However, continuous dosing is not always necessary to maintain therapeutic efficacy. One prospective study by McCreadie et al. [160] indicates that intermittent administration with short interdosing intervals (as modeled in the animal studies described above [9,11,154]) can be as effective as continuous dosing in preventing psychotic relapse. In this double-blind study, patients were randomly assigned to either continue treatment with fluphenazine decanoate given every 2 weeks (continuous treatment, n = 18) or be switched to daily pimozide equivalent given 4 times a week (intermittent treatment, n = 16) [160]. Relapse rates over the next 9 months were similar in both groups. A second prospective study was a 6-month, double-blind, controlled trial in outpatients with schizophrenia stabilized for ≥3 months on oral antipsychotic given once daily [161]. The patients were randomly assigned to either treatment as usual (n = 18) or the same daily dose given orally every other day (n = 17; risperidone = 6, olanzapine = 11). Over the 6-month interval, symptom exacerbation and number of hospital admissions were similar in both groups. Thus, the 17 patients who had a 50% reduction in their maintenance dose given as alternate-day treatment (the “extended dosing” group) had similar relapse rates compared to those who kept taking their treatment as usual once a day [161]. However, reduction in the maintenance dose on one hand and continuous versus intermittent treatment on the other were confounded. To directly evaluate the effects of continuous versus intermittent antipsychotic treatment, a study would have to give the same “equivalent” dose daily versus every other day (e.g., 2 mg risperidone/day once daily versus 4 mg risperidone every other day). “Extended dosing” by giving treatment every other day is one strategy to reduce antipsychotic dose by 50%. The authors did not mention the length of prior antipsychotic treatment or the prior daily milligram dose of the 3 medications taken (risperidone, olanzapine, and loxapine). It is likely that the D2 occupancy was lower than the narrow therapeutic window of 65-72% found by Kapur et al. [138] for the acute/subacute phase and for first-episode schizophrenia. The McCreadie study [160] is more interesting in this respect since patients received a daily dose of oral pimozide 4 times a week (Monday to Thursday; intermittent dosing strategy), which was equivalent to the previous maintenance dose of LA injectable fluphenazine decanoate; intermittent continuous dosing strategy), thus testing the concept of intermittent antipsychotic treatment to achieve minimum therapeutic dosing and prevent dopamine supersensitivity. Similarly, Tsuboi et al. [162] conducted a single-blind, randomized, prospective, 1-year study including patients treated with oral olanzapine (n = 34) and oral risperidone (n = 34). Patients were stabilized for 6 months before entering the study. Patients were randomly assigned to receive either a treatment regimen producing continuous blockade of D2 >65% or a treatment regimen producing noncontinuous receptor blockade >65%. The continuous D2 blockade group had an estimated D2 occupancy >65% at trough and the noncontinuous blockade group had an estimated peak level of D2 occupancy >65% with an estimated trough level of <65%. The noncontinuous group had target doses of 7.1 mg olanzapine/day and 1.9 mg risperidone/day versus 10.4 and 3.4 mg/day for the continuous group, respectively, the latter producing >65% of estimated D2 occupancy. The authors did not find differences between both treatment regimens regarding the prevention of psychotic relapses. Again, here we have low- versus higher-dose maintenance treatment. However, the dosing interval of both drugs is not mentioned, and concomitant medications are not reported. The only information is “choice of dose at the discretion of the subject's physician on record.” Finally, we do not think that the study by Tsuboi et al. [162] is strictly a comparison of continuous versus noncontinuous but also low- versus high-dose treatment. In addition, a PET study by Nyberg et al. [163] showed that continuous D2 receptor blockade >65% was not necessary to prevent psychotic relapse. The study included 9 schizophrenic outpatients stabilized on haloperidol decanoate given intramuscularly every 4 weeks [163]. Despite an average fall of 52% in D2 receptor occupancy at the end of the injection interval compared to the occupancy level 1 week after injection, patients continued to be stable. Uchida and Suzuki [164] came to the same conclusion in their review of all PET and single photon emission tomography studies of LA injectable antipsychotics. They found that the CNS effects as measured by D2 receptor occupancy of LA injectable antipsychotics can persist for several months, and, as such, these medications may be administered at dosing intervals greater than those recommended in product monographs. The Uchida and Suzuki [164] review included a total of 14 studies with LA injectable FGAs (haloperidol decanoate, n = 11, and fluphenazine decanoate, n = 3), and 4 studies with LA injectable SGAs (LA injectable risperidone, n = 3, and LA injectable olanzapine pamoate, n = 1). Lee et al. [153] reached similar conclusions in their 2015 review of the pharmacokinetic data of LA injectable SGAs available in Canada and the USA (LA injectable aripiprazole, olanzapine, risperidone, and 1- and 3-month formulations of paliperidone palmitate). It should be noted that the clinical studies on intermittent or extended dosing cited here included small numbers of patients. Further clinical studies with larger samples are needed. In addition, future studies must also be designed so that minimal therapeutic dose and intermittent dosing are not confounded, thus allowing a dissociation of effects due to dose versus mode of administration. In summary, continuous occupancy of D2 receptors might not always be necessary to trigger the signaling cascades that underlie the antipsychotic effect. In parallel, the work reviewed here, including preclinical findings [9,11,154], also suggests that sustained antipsychotic treatment above the optimal D2 occupancy threshold for maintenance treatment (which appears lower than for acute and first-episode schizophrenia defined by Kapur [138]) could trigger changes that might be detrimental to the patient. This would include tolerance to therapeutic effects and SP. In parallel, work conducted in animals suggests that intermittent dosing would prevent dopamine supersensitivity [9,11,154]. Both the clinical and animal studies reviewed here suggest that an exploration of intermittent dosing strategies in patients is needed. LA injectable antipsychotics can also be given so as to produce intermittent dosing, taking into account the clinical recommendations of Lee et al. [153] and Uchida and Suzuki [164]. Intermittent dosing involves that D2 occupancy levels be high and then low, with each state maintained for approximately equivalent periods of time. Intermittent dosing should be one way to achieve the minimum therapeutic dose and prevent SP. Thus, LA injectable antipsychotics should not be increased rapidly to mask TD or SP except for palliative treatment in TR patients. However, one should avoid intermittent dosing defined as “targeted” antipsychotic treatment. This involves lengthy intervals without treatment and waiting for prodromal symptoms to reappear before restarting antipsychotic drug treatment. Such approaches were reviewed recently and they turned out to be disastrous for patients [161], since this “targeted” approach led to increased relapse episodes and poor outcomes. Instead, intermittent interval dosing, as used in our animal studies [9,11,154] and as explored in patients by Remington et al. [161], should be investigated further. This would involve intermittent antipsychotic administration with short interdosing intervals (e.g., for oral medication: weekends off and then treatment on Monday to Thursday, as in the McCreadie study [160]). Importantly, the interdosing interval must be long enough to permit peaks and troughs in brain levels of antipsychotic/D2 receptor occupancy. We predict that this enables some level of normal dopamine-mediated neurotransmission to occur in between peaks of D2 receptor blockade by antipsychotics, thus avoiding the neuroadaptations that lead to dopamine supersensitivity [165,166]. The interdosing interval to achieve peaks and troughs in antipsychotic brain levels will be a function of the t1/2 of the antipsychotic. For instance, the length of the interdosing interval would be longer for LA antipsychotics and comparatively shorter for short-acting antipsychotics. Finally, while threshold levels of D2occupancy have already been established for first-episode schizophrenia and acute treatment [138], they must still be established for maintenance treatment.

This may be short, as I just took my evening Clonazepam dose which seems to be the only thing that relaxes my neck muscles (eventually) so that I can stay asleep. It often takes effect by giving me thirty or so seconds of warning that I am about to drop off. So I apologize if I accidentally post gibberish; I don't always get enough notice to put the iThingy down and the random key presses that result might post or just erase all my hard work. But I found this website this evening: Dystonia Medical Research Foundation I wanted to share it because it is a very useful resource so far as I have made use of it. But also because reading the info there seems revelatory and I am too hyper to go to sleep without shouting from some rooftop or another first. I could go into great detail--and I might--but in essence the descriptions of many of the typical symptoms of secondary/tardive dystonia are reading like the solution to this giant puzzle I have been trying to solve for a year and a half and I am at once relieved and angered by the possibility that this could be what is going on with my face, eyes, jaw, neck, shoulders, and the occasional twitchy muscle lower to the ground than chest level. Jaw wants to clamp shut day and night: yes that could be dystonia! Eyes sensitive to light when eye and other muscles freaking out: yes that could be dystonia! Painful spasms that follow cyclical but still unpredictable patterns almost exclusively from the neck up: yes! That could be... Etc. Oh and the Inexplicable fatigue: involuntary muscle contractions are just as energy intensive as voluntary ones. Dystonia may make me feel as though I were working out 18-24 hours a day every single day! It would even explain my voracious appetite for protein, which is much like it was when I did work out regularly. The nausea that interferes with my current efforts to stay fed is still a mystery I guess, although I do want to investigate any relation between constant muscle activity and dehydration since it gets worse if I am without water for long and that aggravates any nausea trying to crop up at the time. The question nobody can answer is why a psychiatrist who took his patient off olanzapine after more than twelve years because that patient was beginning to twitch in a Tardive Dyskinesia sort of way would continue to insist that muscle spasms, pain, and fatigue that have not remitted since the drug was discontinued were "not the Zyprexa". I will concede that I may be fixated on this single etiology to the exclusion of other possibilities, but I still find it appalling that he suggested I get checked for mono when I mentioned fatigue (again) this last time around. So anyway. Please bear with the enthusiasm; it is true that there is no cure for tardive dystonia, but for once in what seems like a lifetime of trying to claim appropriate names for myself, I am very keen to find out if this is indeed a socially-recognizable one for the bulk of what currently ails me. I am vacationing in Seattle right now, but will be looking for a neurologist and/or movement disorder specialist when I return to San Francisco. In the meantime I will text this and a few other links to my MD and my therapist to see if they see me in these symptoms as well as I do. I am also going to take my shiny new Medicare card and go shopping for a different psychiatrist. Tardive Dystonia. I understand why I had never heard if it, but prescribing neuroleptics without having heard of it? I know: the propaganda is no respecter of educative rank, but it took only two google searches as to the current knowledge of tardive dyskinesia for me to come across it. Ok I think I might be sleepy enough to ignore the perpetual shrug that my shoulders find themselves fixed in. I hope that the link is helpful to someone else too.

New to the community. Joined after reading Schizor's (forum member) story. I'll try & make this short. Hospitalized twice. (For "psychosis"). Once for a month in psych ward (Oct - Nov 2016), second time for a few weeks. (Feb 2017) For the first time, forced to take Risperidone & Abilify. Approx 10mg. After complaining it was gradually decreased down to 1mg. Upon release from ward, through trial & error, stopped one drug, tried the other & vice versa. Eventually went cold turkey off both drugs. Second hospital stay was given a shot of Invega. It seems you guys know the drill .... Zombie like feeling, loss of balance, stomach pain, pounding headache, face numbness, involuntary muscle movements, aches, sore eyes, insomnia etc ... After constant arguments, battles & calls to local pharmacists ... Decided to go off the drugs cold turkey. Again it seems you guys know the drill .... After constant nights of bad withdrawals ( a few weeks or so), kinda - sorta made it through only to still have major insomnia, lack of motivation, no energy, weird thoughts, sensitivity to lights & noise, jerky movements, aggression, a bit of sexual dysfunction & so on. Ladies & gents ..... What now ??? I feel exactly like Schizor did. Only wanna sleep but can't really, only wanna eat but don't feel satisfied, lack of emotion & stone cold thoughts, loss of character etc ..... On top of all this I have legal issues & may face jail time. A nightmare is almost an understatement when it comes to these drugs. It's also caused me to become completely paranoid of any doctor diagnosis, (psychosis !?? ... More like psychosis induced) psychiatrist, hospital, medical help of any sort. Thanks for reading (if ya did).

Hi everybody! I'm Finnish, so please excuse my english, I'm very used to reading it, but not necessary writing myself. I try to keep my story short, but in a nutshell I was put on Sepram 20mg (Citalopram?, which later was changed to Escitalopram 15mg) and Olanzapin 5mg because of my depression and ocd. Now, I have to say that I really did not feel that depressed to begin with and in hindsight, I was really doing well (especially compared to now) without any meds whatsoever. Anyway, I took them for roughly 2 and a half to 3 weeks and then stopped, foolishly I might add, them both pretty much cold turkey before starting my ECT therapy. I should have discussed about it with someone, but the ECT therapy got started so suddenly and I did not really have an opportunity to talk about my concerns with anyone. I just felt uncomfortable having that many external things affecting my brain at the same time, so I figured I better get of the meds for my own peace of mind. It really didn't even occur to me, that getting off these meds could have any negative effects, cold turkey or otherwise. So I stopped taking them and about the halfway in my ect therapy, I started having increased anxiety and panic attacks. I also got one of those "brain zaps", that really scared me and started one pretty rough anxiety attack. Without knowing any better, I blamed the ect therapy for messing up my brain, but now later came to realize that I was, and still am, suffering from ssri and antipsychotic withdrawal symptoms. I feel restless, anxious, nauseous and have trouble sleeping. I have lost my appetite and really only want to lay down in quiet most of my time. I'm scared easily and for the first week since the symptoms appeared I was having constant panic attacks. I was certain that I was going to die and with the lousy feeling I'm having, still get these feelings, just not so overwhelmingly. Sometimes I'm feeling really cold, other times like I'm having a fever. I feel sluggish, constantly kinda "out of it" and have these internal tremors/shakes. My palms are sweaty most of the time and I'm having trouble to concentrate or doing pretty much anything. It's been two weeks since the symptoms started and I've really had enough of them. I took multivitamins from the start, but just started taking extra magnesium and fish oil, hoping to relieve my symptoms. Now, I was only taking the drugs for a short while and with pretty low doses, but still. I feel pretty horrible 24/7 and hope there's light at the end of the tunnel. Oh yeah, just to add: I took Escitalopram for maybe four days before quitting, Sepram for the couple of weeks before that. I just hope I get through this and did not cause any long lasting damage to myself with this. Thanks for letting me went out a bit!

I'm 32 with no prior history of mental health problems. I had a manic and psychotic episode in late May of 2015 after to weeks of starting CPAP therapy for severe sleep apnea. I take a cab to my hometown and admit myself to the hospital because I'm freaked out by my behaviour and my feelings, and after being evaluated I'm given seroquel (25 mg 2x day) and risperidone (2 mg before bed) and end up staying at the psychiatric ward for 5 weeks. After leaving the hospital, I suddenly have no libido and significant fogginess and anhedonia. I get off seroquel and get prescribed lithium (450 mg initially, later 600 mg) because I can't stay awake on the seroquel. I quit the risperidone and then the lithium because I can't take being a fat, bored, pill-dependent zombie. I'm struggling with the risperidone withdrawl, but I'm able to work full time, I'm gradually getting less bored and anxious, and my libido is starting to come back. (I seldom have acute sexual desire, but I'm actually able to get an erection and to get myself off when I make the effort to fantasize about stuff that turns me on, whereas I went weeks without bring able to have an erection or, naturally, to orgasm while I was gullibly poisioning myself with risperidone) I'm just very frustrated that I was never advised that risperidone had such nasty side effects, but I did go from being manic and euphoric to pretty well losing touch with reality. I think I had a dopamine overload because the CPAP therapy improved my sleep and my energy level so incredibly that it felt like a bloody miracle. I started feeling like I was on ecstasy or on a good crystal meth trip or something (wouldn't know...I've only had booze and pot, but based on what I've read...). I felt this incredible euphoria and sense of empathy, and I was writing political rhetoric and coming up with grandiose idea to make the world a better place and to make my place of employment kick butt, but then I lost touch with reality, destroyed some possessions, and blew $200 on a cab ride. Anyways, I just want to be happy again. I want to take pleasure in the stuff that I used to like before all this happened, I want to lose weight and get myself in shape (making process on this front...But I suppose when your BMI is 40, you can lose weight even when lithium and risperidone are dragging you down), I want to fall in love with my job and with my ideals again, I want to be a better version of the person that I was before I got treatment for my sleep apnea. I know it's not the CPAP therapy that does that to me. All it does is ensure that I can breath when I sleep. Common sense dictates that when you stop breathing 100 times an hour and keep waking up and failing to reach REM sleep and spending your days micro-napping, you obviously need medical addition It's dealing with the fact that I experienced something very similar to drug-induced psychosis for what I assume was a dopamine overload, hallucinated the second coming of Jesus Christ while I was psychotic, was surrounded by people with delusional beliefs when I was at the psychiatric ward that fed into the craziness, and then, because of the hallucinations and the religious delusions prior to my coming to grips with the risperidone side-effects, thought I was in Hell. In reality, the anhedonia, the anxiety, and the libido problems were just consequences of my having to deal deal with one of Satan's poisons here on Earth: risperidone. I wish everyone peace, love, happiness, fulfilment, freedom from psychiatry, and awesome sex! And please let and every one of us get better!

Antipsychotics side-effects check list http://www.cqaimh.org/pdf/tool_asc.pdf I think a lot of these also apply to antidepressants as well. I developed some of these symptoms even after 4 years on Pristiq. Doctors refused to acknowledge that it was a side effect, saying that you cannot develop new side effects after such a long period of time. I tried to cut and paste the file, but it's password protected. antipsychotic side effects checklist.pdf

Someone very close to me is thinking about coming off Quetiapine. I keep reading that a reduction of 10% a month should be safe, I would just never forgive myself if my advice in any way harmed him. So I wanted to describe the situation and ask for a second opinion. Diagnosis: Autism (type 1), depression, anxiety, under review: possible borderline personality disorder (I don't see it). Current meds: Pregabalin 600mg, Fluoxetine 20mg, Quetiapine 300mg. self medicating responsibly with cannabis. Age 23 now, Initially prescribed Quetiapine around 3 years ago "for insomnia". Dosage was then upped in 2 increments, most recently late 2014, to 300mg even though he feels his symptoms are adequately managed with the other 2 meds. He feels that he has never felt any benefits of Quetiapine and is suffering from a myriad of distressing side effects since the last dosage increase including a feeling of lost intelligence, visual disturbances and sudden weight gain. He has since been neglected by mental health service in his area and the whole thing stinks of incompetence. He has tried to come off it once before but typical doctor reduced way too fast. At 200mg, the extreme tinnitus, visual snow and other withdrawal symptoms were too much and he was reinstated. As someone who has experienced life changing-ly serious side effects and withdrawal myself I can see why even the thought of facing withdrawal again sends him into panic, but he still wants to reclaim what he feels he's lost. Currently discharged from mental health services it will take 3 months to get a 1 off appointment which they then refuse to follow up or review him (he hasn't even had a blood test in yonks). I advised that it is totally possible to recover at least 99% from anti psychotic withdrawal, especially at his age, if done at a snail's pace. I have suggested manually chopping his tablets up seeing as the doctors don't want to know. My only fear is that the Quetiapine could be contributing to his stability in some way by means of interacting with the other meds but this seems very unlikely given that he has never described any psychotic symptoms and remembers his symptoms improving dramatically with the introduction of the other meds, NOT the antipsychotic. What are your thoughts on the course of action? Do you have any tips or resources for this? Thank you so much.